Drug Profile
Research programme: neurodegenerative disorders therapy - Aquinnah Pharmaceuticals
Alternative Names: TDP-43 stress granulesLatest Information Update: 03 Nov 2023
Price :
$50
*
At a glance
- Originator Aquinnah Pharmaceuticals
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action TDP-43 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia; Progressive supranuclear palsy